On 9 November 2026 China's Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) published the Technical Guideline on Safety Information Reporting and Risk Communication in Drug Clinical Trials (药物临床试验安全信息报告与风险沟通交流技术指导原则), Notice No. 52 of 2026 [1]. The notice is dated 4 November, states that the guideline was reviewed and agreed by NMPA, and applies from the date of publication [1]. It is a technical guideline, not a regulation. The text says that it represents the regulator's current views and "does not have mandatory legal binding force" (不具有强制性的法律约束力) [1].
The guideline matters because of what sits behind it. Until 31 August 2026, China's Good Clinical Practice (GCP) required sponsors to expedite every suspected unexpected serious adverse reaction (SUSAR) to all participating investigators, institutions and ethics committees [3]. The revised GCP, in force since 1 September 2026, replaced that with a proportionality test: the way SUSARs reach principal investigators (PIs) and ethics committees (ECs) must match the urgency of action required and the change in the product's safety profile [2]. Notice 52 explains how to apply that test. For pharmacovigilance and clinical-safety teams running China as part of a multi-region programme, it introduces a third distribution model alongside the EU's EudraVigilance-centred route and the US investigational new drug (IND) safety report.
The English translations in this article are Safety Strategy's own, made from the official Chinese texts. Where wording carries weight, the Chinese is given.

What the guideline requires
The guideline focuses on how safety reports that are also submitted to CDE travel between sponsor, PIs and ECs [1]. It does not change reporting to CDE itself: for that, sponsors are told to follow the relevant ICH guidelines and CDE's own standards and procedures [1]. Its flowchart shows SUSARs going to CDE under ICH E2A and E2B, and other potentially serious safety information going to CDE within 15 days of being identified as such [1].
Site to sponsor and ethics committee. Unless the protocol or investigator's brochure (IB) exempts an event, the PI should report every serious adverse event (SAE) in writing to both the sponsor and the EC immediately after becoming aware of it, "recommended as within 24 hours", followed by detailed written follow-up [1]. A common template is suggested, with data elements taken from Appendix 8 of the CIOMS VI report [1]. PIs must read and acknowledge SUSAR reports and other serious safety information from the sponsor, consider whether participants' treatment needs adjusting and, if necessary, talk to participants early [1].
Sponsor to PIs and ECs: the SUSAR principle. The way a sponsor submits SUSARs to PIs and ECs "should be proportionate to the urgency of the action required and to the change in the safety profile of the investigational drug" (应当与需采取措施的紧迫性和试验药物安全性特征的变化相称) [1]. Urgency is judged on seriousness (the effect on life or function), whether the risk can be acted on, and whether delay would expose participants to greater risk [1]. A change in safety profile means new information that differs from what is known: a new serious risk, a clear rise in the frequency or severity of an identified risk, or risks clustering in a particular population [1]. Because a single SUSAR rarely shows its effect on the whole trial, sponsors are also expected to analyse SUSARs in aggregate promptly [1].
Three routes for individual SUSARs. The guideline recommends using the likely effect of a finding on the conduct of the trial as the main criterion [1]:
- SUSARs that could lead to changes to the protocol, IB or informed consent form, or to pausing or stopping the trial (including pausing or stopping enrolment or dosing), "should" be expedited to PIs and ECs, and reported immediately where necessary in an emergency [1].
- SUSARs with no direct effect on trial conduct but which materially update investigators' understanding of the drug's risks — "particularly in early-phase trials where safety data are still limited" — are recommended for expedited reporting to PIs as well [1]. The text names PIs, not ECs, for this group.
- All other individual SUSARs are recommended for a monthly report to PIs and ECs, consisting of an overall safety assessment with a line listing [1]. For different trials of the same drug at the same institution, the sponsor may make one submission per drug to the EC, listing all relevant trial titles and numbers, rather than repeating the same report trial by trial [1].

Timelines and format. An "immediate" report is recommended to mean within 24 hours of the sponsor becoming aware [1]. For an "expedited" report, the guideline refers to ICH E2A: no later than 7 days after awareness for fatal or life-threatening cases, and no later than 15 days for others [1][8]. The 24-hour limit is the guideline's own; ICH E2A sets only the 7-day and 15-day limits for reporting to regulators [8]. The CIOMS I form is recommended [1]. Reports may be on paper or electronic, as the institution decides; email or an institutional platform is encouraged [1]. Reporting to a site is recommended to start no later than the site's initiation date and end no earlier than the last participant's final follow-up at that site; for sites that enrolled no one, it ends at the close of enrolment or site closure [1]. SUSAR reports in blinded trials must stay blinded [1].
Other potentially serious safety information. This covers information that clearly affects the benefit-risk assessment, may change how the drug is used, or affects the overall development programme. The guideline's examples include a clinically important rise in the frequency of a known serious reaction, lack of efficacy that harms patients with a life-threatening disease, a major new animal finding such as carcinogenicity, a trial paused or stopped for safety reasons, an important risk found in aggregate analysis, and any other urgent issue [1]. It must be expedited to PIs and ECs "no later than 15 days after it is identified" as such, and "the sponsor must not evade the reporting obligation by delaying assessment" [1]. Important risks found in aggregate SUSAR analysis go by this route [1].
Regulatory instructions. CDE's risk-control notices, notices to pause or terminate a trial and risk-management letters must be forwarded to ECs and PIs within the expedited timeline; the flowchart puts this at 15 days from receipt [1].
DSUR. The guideline recommends that sponsors give PIs and ECs the executive summary of the development safety update report (DSUR) and the line listing of serious adverse reactions; PIs and ECs may ask for other sections [1]. The timing follows ICH E2F, "within two months after the development international birth date (DIBD)" [1]. ICH E2F itself already describes the executive summary as suitable for ethics committees, supplemented by serious adverse reaction line listings [9].
Ethics committees. ECs should have written procedures for receiving and reviewing safety reports, should issue receipts, and should review in a way proportionate to urgency and to the change in safety profile [1]. Where an EC decides to pause or stop a trial for safety reasons, it may contact CDE directly [1].
| Item | To | Timing | Wording |
|---|---|---|---|
| SAE at site | Sponsor and EC | Immediately; 24 h recommended | "Should" report [1]; binding duty in GCP 2026 Art. 26 [2] |
| Trial-impacting SUSAR: could change the protocol, IB or consent, or pause or stop the trial | PIs and ECs | Expedited: ≤7 days (fatal or life-threatening), ≤15 days (other); immediate (≤24 h) in emergencies | "Should" [1] |
| Informative SUSAR: no direct effect on conduct, but updates investigators' view of risk | PIs | Expedited | Recommended [1] |
| All other individual SUSARs | PIs and ECs | Monthly overall safety assessment with line listing | Recommended [1] |
| Important risk from aggregate SUSAR analysis | PIs and ECs | As other potentially serious safety information | "Should" [1] |
| Other potentially serious safety information | PIs and ECs | ≤15 days after it is identified as such | "Should"; assessment must not be delayed [1] |
| CDE risk-control, pause or termination notices, and risk-management letters | PIs and ECs | Expedited; ≤15 days from receipt (flowchart) | "Should" [1] |
| DSUR executive summary and serious adverse reaction line listing | PIs and ECs | Within two months after the DIBD, per ICH E2F | Recommended [1][9] |
What changed: from "all SUSARs to everyone" to proportionality
The change happened in two steps, and both matter.
The 2020 GCP (Announcement No. 57 of 2020) required the sponsor to expedite SUSARs "to all investigators and clinical trial institutions participating in the trial, and to ethics committees", and also to report them to the drug regulator and the health authorities [3]. Investigators, in turn, had to report sponsor-provided SUSARs to their EC [3], and ECs were told to require investigators to report "all" SUSARs [3]. Investigators had to report SAEs to the sponsor; the 2020 text did not require routine SAE reports to the EC [3]. Separately, CDE's 2018 standard set the expedited timelines for reports to CDE: 7 days for fatal or life-threatening SUSARs, with follow-up within a further 8 days, and 15 days for others, with day 0 being the day the applicant first becomes aware [4]. The same standard covers SUSARs from both Chinese and overseas sites and requires reports in Chinese [4]. CDE's 2020 DSUR rule set an annual cycle based on the DIBD, with the first DSUR due within two months after the first DIBD following approval of a trial in China [5]. CDE's 2020 rule on safety information during trials (Article 17) asked applicants to inform institutions, ECs and investigators of CDE risk-control, pause or termination notices "promptly" (及时), without a day count [6]; Notice 52 now puts such notices on a 15-day clock [1].
The 2026 GCP (Announcement No. 50 of 2026, signed 21 May 2026, effective 1 September 2026, repealing the 2020 text) rewrote these provisions [2]. Article 44(3) requires SUSARs and other potentially serious safety information to be expedited to CDE, and requires SUSAR reporting to PIs and ECs to be proportionate to urgency and to the change in safety profile [2]. Regulatory risk-handling requirements, other potentially serious safety information and urgent safety issues must still go to ECs and PIs within expedited timelines [2]. Article 26(2) now requires PIs to report SAEs to the EC as well as the sponsor [2]. Article 14(5) asks ECs to review SUSARs, other serious safety information and DSUR information proportionately [2]. NMPA's accompanying questions and answers describe the GCP as a normative document that serves as a basis for enforcement, and say that ICH E6(R3) has been implemented in full in China after 31 March 2026 [2].
The proportionality wording is close to ICH E6(R3), section 3.13.2(d): reporting of SUSARs to investigators, institutions and IRBs/IECs "should be undertaken in a manner that reflects the urgency of action required and should take into consideration the evolving knowledge of the safety profile", and "in some regions, periodic reporting of line listings with an overall safety assessment may be appropriate" [7]. Notice 52 turns that permissive international text into specific Chinese routes, a monthly cadence and fixed recipients.
| Topic | 2020 GCP and CDE (to 31 Aug 2026) | 2026 GCP (from 1 Sep 2026) | Notice 52/2026 (from 9 Nov 2026) |
|---|---|---|---|
| SUSARs to investigators and ECs | All SUSARs expedited to all investigators, institutions and ECs [3] | Proportionate to urgency and change in safety profile [2] | Three routes: expedited, expedited to PIs only, or monthly [1] |
| Who sends SUSARs to the EC | Sponsor, and investigator forwards sponsor's SUSARs [3] | Sponsor submits to PIs and ECs [2] | Sponsor, with one EC submission per drug per institution allowed [1] |
| SAE from site | To sponsor immediately [3] | To sponsor and EC immediately [2] | Recommended within 24 h [1] |
| Timelines to sites | Expedited, no day count in GCP [3] | Expedited timelines [2] | 24 h (immediate), 7 or 15 days (per ICH E2A), 15 days (other serious information) [1] |
| Regulatory recipient of SUSARs | Drug regulator and health authorities [3]; CDE at 7 or 15 days [4] | CDE [2] | Unchanged; ICH E2A/E2B to CDE [1] |
| DSUR to sites | DSUR information to all investigators, institutions and ECs [3] | Relevant information as required [2] | Executive summary and serious adverse reaction line listing [1] |
How China compares with the EU and the US
The three systems use the same expedited clocks for regulators: 7 days for fatal or life-threatening cases and 15 days for others [4][10][12]. They differ in who else is told, through which channel, and on what threshold.
In the EU, Regulation (EU) No 536/2014 (the Clinical Trials Regulation, CTR) is directly applicable law. Sponsors report SUSARs electronically to EudraVigilance — including SUSARs from third-country sites in the same trial and, under defined conditions, from third-country-only trials of the same active substance — within 7 days for fatal or life-threatening cases and 15 days for others [10]. An incomplete fatal or life-threatening report must be completed within a further 8 days [10]. EMA forwards the information to the Member States concerned, and ethics committees are involved where national law provides [10]. The CTR's questions and answers state that additional direct submissions from sponsors to ethics committees "are not foreseen" [11]. The CTR does not mention SUSAR reporting to investigators. The Q&A, which is not legally binding, advises informing investigators of changes to the safety profile rather than sending individual SUSARs, normally through periodic blinded line listings with a summary analysis, with individual reports only where unblinded data are needed to manage a case [11]. Other unexpected events affecting benefit-risk go to Member States through the EU portal (CTIS) within 15 days, and urgent safety measures within 7 days of being taken [10]. Investigators report SAEs to the sponsor within 24 hours [10].
In the US, 21 CFR 312.32 is a regulation. The sponsor must notify FDA and all participating investigators in an IND safety report within 15 calendar days of determining that information qualifies, and must notify FDA of unexpected fatal or life-threatening suspected adverse reactions within 7 calendar days of initial receipt [12]. The threshold is narrower than a SUSAR as usually defined: a serious, unexpected adverse event is reportable only if there is evidence to suggest a causal relationship, for example a single case of an event strongly associated with drug exposure, or an aggregate imbalance [12]. Investigators report SAEs to the sponsor "immediately" [13] and must "promptly" report unanticipated problems to the IRB [13]. FDA's December 2025 investigator guidance, which replaced the 2009 IRB guidance, states that investigators must submit IND safety reports to the IRB because FDA considers them unanticipated problems; the sponsor may submit on the investigator's behalf if documented [15]. FDA's sponsor guidance recommends sending investigators only the narrative summary of an aggregate IND safety report, without the unblinded individual cases [14]. Both guidances are non-binding [14][15].
| Element | China | EU (CTR) | US (IND) |
|---|---|---|---|
| Legal status | Guideline, stated as non-binding [1]; GCP is a normative document [2] | Regulation [10]; Q&A non-binding [11] | Regulation [12][13]; FDA guidance non-binding [14][15] |
| Fatal or life-threatening SUSAR, to the regulator | CDE, ≤7 days (+8 days follow-up) [4] | EudraVigilance, ≤7 days (+8 days to complete) [10] | FDA, ≤7 calendar days [12] |
| Other SUSAR, to the regulator | CDE, ≤15 days [4] | EudraVigilance, ≤15 days [10] | FDA, ≤15 calendar days after determination [12] |
| Individual SUSARs to investigators | Tiered: expedited (7/15 days, 24 h if urgent) or monthly [1] | Not in CTR; Q&A favours periodic blinded line listings [11] | All IND safety reports to all participating investigators, ≤15 days [12] |
| SUSARs to ethics committees or IRBs | Sponsor direct: expedited if trial-impacting, otherwise monthly [1] | No direct sponsor submission; via Member State [10][11] | Investigator to IRB "promptly" (or sponsor on their behalf) [13][15] |
| Other serious safety findings | To PIs and ECs ≤15 days after identification [1] | Unexpected events to Member States ≤15 days; urgent safety measures ≤7 days after measures taken [10] | IND safety report ≤15 days (other studies, animal data, increased rate) [12] |
| SAE from site | Sponsor and EC, immediately (24 h recommended) [1][2] | Sponsor, ≤24 h [10] | Sponsor, immediately [13] |
| Annual safety report | DSUR to CDE [5]; executive summary and SAR line listing to PIs and ECs within two months after the DIBD [1] | Annual safety report within 60 days after the data lock point [11] | IND annual report within 60 days of the IND anniversary [13] |

The practical consequence is that China is now the only one of the three jurisdictions whose rules direct the sponsor itself to send individual SUSARs to ethics committees, and then only for the subset that could affect trial conduct. In the US the duty to inform the IRB sits with the investigator, although the sponsor may submit on the investigator's behalf [15]. China is also the only one that sets a fixed periodic cadence (monthly) for the remaining cases. The EU leaves the frequency of investigator updates to the sponsor [11]. In the US, cases below the causality threshold are not sent to investigators as IND safety reports; adverse experiences are summarised for FDA in the IND annual report [12][13].

What it means for multi-region sponsors
The following points follow directly from the texts above. They are not a substitute for site-level and local regulatory advice.
- Write a China-specific distribution rule into the safety management plan. The tier assigned to each SUSAR is a sponsor judgement on urgency and safety-profile change [1]. Define who makes it, the criteria, and how it is documented, so the decision can be reconstructed at inspection.
- Do not assume the EU periodic line listing fits China as it stands. China recommends a monthly overall safety assessment with a line listing, sent to both PIs and ECs, with per-drug EC submissions allowed [1]. The EU Q&A leaves frequency open and does not route the listing to ECs [11]. A single global template can serve both only if it meets China's cadence, content and recipients.
- Decide how to handle the "informative" tier. Early-phase programmes should set criteria for SUSARs that change investigators' understanding of risk without changing trial documents, since these are recommended for expedited reporting to PIs [1].
- Align global triggers with China's 15-day route. A finding that leads to a US IND safety report under 21 CFR 312.32(c)(1)(ii)–(iv) [12], or to an EU unexpected-event notification or urgent safety measure [10], will often also be "other potentially serious safety information" in China, due to PIs and ECs within 15 days of identification [1]. The guideline warns against delaying assessment [1].
- Track several clocks. China runs from sponsor awareness (24 hours, 7 days, 15 days), from identification (other serious information), and from receipt (CDE notices) [1]. The US 15-day clock runs from determination and the 7-day clock from initial receipt [12]. The EU runs from awareness [10].
- Forward CDE instructions. Risk-control, pause and termination notices and risk-management letters need to reach ECs and PIs within 15 days of receipt [1].
- Check each ethics committee's procedures. Institutional rules may lag behind the guideline. The ethics committee of Peking University First Hospital, in rules issued on 7 September 2026, still asked sponsors to report individual SUSARs to PIs and the EC within 7 or 15 days, with summary reports at least every six months [16]. Site contracts and EC submission plans should reflect what each committee will actually accept.
- Prepare the DSUR extract. Plan the executive summary and serious adverse reaction line listing for Chinese PIs and ECs on the DIBD cycle [1][9].
- Keep site reports blinded and fix the reporting window per site, from site initiation to the last participant's final follow-up [1].
- Leave CDE reporting unchanged. The guideline does not alter expedited E2B reporting to CDE; it refers sponsors to the ICH guidelines and CDE's existing standards, under which overseas SUSARs are included and reports are made in Chinese [1][4].
What is established and what is not
Established: the guideline's text, its non-binding status and its application from 9 November 2026 [1]; the binding proportionality principle in Article 44(3) of the 2026 GCP since 1 September 2026 [2]; the end of the 2020 rule that all SUSARs be expedited to all investigators and ECs [2][3]; and the timelines set out above.
Not yet clear from the official texts:
- Overseas cases. The guideline does not say whether SUSARs from non-Chinese sites, or from other trials of the same drug, belong in reports to Chinese PIs and ECs. The 2018 standard covers overseas cases for reporting to CDE [4].
- Monthly mechanics. The text does not define the monthly period, the data lock point, or whether a nil report is expected.
- Language. Reports to CDE must be in Chinese [4]; Notice 52 does not state a language for reports to sites.
- ECs and the informative tier. The second route names PIs only [1]; whether ECs expect copies is for each committee.
- DSUR timing. "Within two months after the DIBD" [1] differs slightly from ICH E2F's 60 calendar days after the data lock point [9]. CDE's 2020 rule ties the DSUR cycle to the DIBD anniversary [5].
- Transition. No transitional period is stated for ongoing trials [1].
- Inspection approach. How NMPA inspectors will assess sponsors' tiering decisions under a non-binding guideline, against the binding GCP principle, remains to be seen.
China has moved from the most prescriptive model of the three to a risk-proportionate one that is closer in spirit to ICH E6(R3) and the EU, while keeping direct reporting to ethics committees for the cases that matter most. For safety teams, the work is mainly in triage criteria, documentation and site-level alignment, not in new regulatory submissions.
References
- CDE: Notice on publishing the Technical Guideline on Safety Information Reporting and Risk Communication in Drug Clinical Trials (Notice No. 52 of 2026), dated 4 November 2026, published 9 November 2026, with guideline PDF
- NMPA, NHC, NATCM and NDCPA: Announcement on publishing the Good Clinical Practice for Drug Clinical Trials (Announcement No. 50 of 2026), signed 21 May 2026, effective 1 September 2026, with questions and answers
- NMPA and NHC: Announcement on publishing the Good Clinical Practice for Drug Clinical Trials (Announcement No. 57 of 2020), effective 1 July 2020 (State Council policy library)
- CDE: Standards and Procedures for Expedited Reporting of Safety Data during Drug Clinical Trials, 27 April 2018
- CDE: Rules for the Management of Development Safety Update Reports (Trial) (Notice No. 7 of 2020), 1 July 2020
- CDE: Rules for Assessment and Management of Safety Information during Drug Clinical Trials (Trial) (Notice No. 5 of 2020), 1 July 2020
- ICH E6(R3) Guideline for Good Clinical Practice, adopted 6 January 2025
- ICH E2A Clinical Safety Data Management: Definitions and Standards for Expedited Reporting, Step 4, 27 October 1994
- ICH E2F Development Safety Update Report, Step 4, 17 August 2010
- Regulation (EU) No 536/2014 on clinical trials on medicinal products for human use, Articles 40–44, 52–54 and Annex III
- European Commission: Clinical Trials Regulation (EU) No 536/2014 Questions & Answers, version 7.4, October 2026 (EudraLex Volume 10)
- 21 CFR 312.32 IND safety reporting (eCFR)
- 21 CFR 312.33, 312.64 and 312.66: annual reports, investigator reports and assurance of IRB review (eCFR)
- FDA: Sponsor Responsibilities — Safety Reporting Requirements and Safety Assessment for IND and Bioavailability/Bioequivalence Studies, Guidance for Industry, December 2025
- FDA: Investigator Responsibilities — Safety Reporting for Investigational Drugs and Devices, Guidance for Investigators, Industry, and IRBs, December 2025
- Peking University First Hospital Biomedical Research Ethics Committee: Timelines and requirements for submitting safety information to the ethics committee, 7 September 2026
Safety Strategy · Pharmacovigilance and safety risk management · Vaud, Switzerland
This article is for information only and is not medical or regulatory advice.
Related services: regulatory filings including DSURs and signal management and benefit-risk assessment.
Follow Safety Strategy on LinkedIn (opens in a new tab) for new articles and updates. Back to all news